Search

Your search keyword '"Amerio, Paolo"' showing total 16 results
Start Over Author "Amerio, Paolo" Topic dermatology
16 results on '"Amerio, Paolo"'

1. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Author

Costanzo A, Amerio P, Asero R, Chiricozzi A, Corazza M, Cristaudo A, Cusano F, Ferrucci SM, Nettis E, Patrizi A, Patruno C, Peris K, Picozza M, Stingeni L, and Girolomoni G

Subjects
Adult, Allergists, Child, Consensus, Dermatologists, Hospitals, Humans, Quality of Life, Asthma, Dermatitis, Atopic diagnosis, Dermatology, Venereology
Abstract

Atopic dermatitis (AD) is a common chronic-relapsing inflammatory skin disease, burdened by various comorbidities. AD most commonly occurs in children but may persist or present in adulthood becoming a lifelong condition. Therefore, AD requires an effective long-term treatment improving disease signs and symptoms but also of patients' quality of life (QoL). However continuous long-term use of most traditional AD immunosuppressive treatments is not recommended for safety reasons or insufficient efficacy data. Despite the available guidelines, there is still need for knowledge of AD long-term treatment, taking into account new disease measures and recent treatment options. Five Italian scientific societies implemented a joint consensus procedure to define the most appropriate clinical practice for the long-term management of adult moderate-severe AD. Through a modified Delphi procedure, consensus was reached by overall 51 Italian dermatologists and allergists (The Italian AD Study Group) experienced in the management of adult AD on 14 statements covering three AD areas of interest, namely diagnosis, definition of disease severity and clinimetrics, and a treat-to-target approach. This paper reports and discusses the agreed statements, which define disease and patient impact measures, therapeutic approach, and a treatment decision algorithm to support clinicians in the long-term management of adult patients with moderate-to-severe AD in their daily clinical practice.

Published
2022
Full Text
View/download PDF

3. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Hansel, Katharina, Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., and Peris, K.

Subjects
Dupilumab Therapy, Antibodies, Monoclonal, Humanized, Disease Progression, Humans, Treatment Outcome, COVID-19, Dermatitis, Atopic, Dermatitis, Atopic dermatitis, Dermatology, Dupilumab, Antibodies, Atopic, Settore MED/35, Monoclonal, Immunology and Allergy, human, Humanized, treatment outcome, Antibodies, Monoclonal, Humanized, COVID-19, Dupilumab Therapy, disease exacerbation, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human, monoclonal antibody, atopic dermatiti
Abstract

N/A

Published
2022

4. Dermatology Publications on COVID-19 during the First Pandemic Year: Creativity or Opportunism?

Author

Amerio, Paolo, Giuliani, Federica, Coppola, Marco, Lobefaro, Fabio, and Gualdi, Giulio

Subjects
*COVID-19 pandemic, *PANDEMICS, *DERMATOLOGY, *DATABASE searching, *CREATIVE ability
Abstract

Introduction: Dermatologists had to face several challenges during the COVID-19 pandemic. In this scenario, a large amount of data has been produced and published. Objectives: We present a literature analysis of publications on COVID-19 in the dermatology field in the first year of the pandemic. Methods: The research was carried out by searching the PubMed database using keywords related to "COVID-19" combined with the keyword "Dermatology" in the "affiliation" search field and collecting articles published from February 2020 to December 2020. Results: A total of 816 publications from 57 countries were retrieved. Overall, publications increased notably along the timespan considered in this study and appeared to be closely linked to pandemic progression in different countries. In addition, article types (i.e., commentaries, case reports, original research) appeared to be strictly influenced by the pandemic's progression. However, the number and category of these publications may raise questions regarding the scientific relevance of the messages reported. Conclusions: Our analysis provides a descriptive quantitative analysis and suggests that publications do not always respond to real scientific needs but are sometimes linked to a need/opportunity for publication. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

5. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iris, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study group, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, Vezzoni R, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo', S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study, Group, Balestri, R, Bernardini, N, Belloni Fortini, A, Burlando, M, Caldarola, G, Campione, E, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, Mt, Franchi, C, Esposito, M, Foti, C, Gambini, Dm, Gambardella, A, Girolomoni, G, Giunta, A, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, Ml, Patrizi, A, Pellacani, G, Richetta, Ag, Rosi, E, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Venturini, M, Vezzoni, R, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Piaserico S., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Rossi M.T., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo' S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., and Peris K.

Subjects
0301 basic medicine, Male, Clinical Biochemistry, Disease, Cohort Studies, 0302 clinical medicine, Drug Discovery, Receptors, 80 and over, Medicine, Aged, 80 and over, education.field_of_study, Incidence (epidemiology), Incidence, Interleukin-17, psoriasis, Middle Aged, dermatology, sars-CoV-2, Italy, biological therapy, 030220 oncology & carcinogenesis, Cohort, Biological Product, COVID-19, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Adult, Aged, Biological Products, Biological Therapy, Chronic Disease, Humans, Pandemics, Psoriasis, Receptors, Interleukin, Risk Assessment, Tumor Necrosis Factor-alpha, Young Adult, Cohort study, Human, medicine.medical_specialty, Population, 03 medical and health sciences, Settore MED/35, Internal medicine, education, Pharmacology, Psoriasi, Pandemic, business.industry, Biological product, Interleukin, medicine.disease, Clinical trial, 030104 developmental biology, SARS-CoV-2, Cohort Studie, business
Abstract

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

6. Defining the Profile of Patients with Primary Merkel Cell Carcinoma in Central Italy: A Retrospective Analysis.

Author

Gualdi, Giulio, Ferrara, Gerardo, Simonacci, Marco, Fargnoli, Maria Concetta, Sollima, Laura, Molinelli, Elisa, Campanati, Anna, Mazzocchetti, Giampiero, Giacchetti, Alfredo, and Amerio, Paolo

Subjects
DERMATOLOGISTS, RETROSPECTIVE studies, DISEASE incidence, IMMUNOSUPPRESSION, LEG, SYMPTOMS, MEDICAL records, MERKEL cell carcinoma
Abstract

Simple Summary: Merkel cell carcinoma is rarely suspected and often misdiagnosed in the clinical setting. Robust epidemiological data are missing, contributing to a lack of knowledge of this type of tumor among clinicians. We aimed to demographically and clinically characterize Merkel cell carcinoma patients and the tumor's features through a multicenter real-world analysis of patients from Central Italy from 2015 to 2020. Our study revealed a higher incidence rate compared to the one estimated for the Italian population, with the lower limbs as the anatomical site affected the most. We also report that several specialists are involved in the first-line management of the pathology. In this light, a deeper knowledge of this tumor is advised. Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer that usually occurs in elderly people on sun-exposed areas, with a predisposition to local recurrence. Evidence suggests a growing incidence over the past decade; however, robust epidemiologic data are still lacking. We describe the MCC population in clinical practice in a retrospective analysis of demographic, clinical, and tumor characteristics from medical records of primary MCC patients, between 2015 and 2020, at six dermatology clinics in Central Italy. Ninety-four patients were included (57.4% male; mean age 78.2 ± 10.1 years, range 47–99 years). The estimated incidence rate of MCC was 0.93 per 100,000 inhabitants/year. Lower limbs were the most frequently affected site (31.5%), and 54% of patients for whom information was available were immunosuppressed. Lymph node involvement was reported in 42.5% of patients, and distant metastases in almost 20%. Most patients underwent surgery for tumor excision and were mainly referred to specialized dermatology clinics by dermatologists (47.9%) and general surgeons (28.7%). Apart from the relatively balanced prevalence of MCC in men and women, the predominant location on lower limbs, and the higher incidence rate compared with previous reports in Italy, this population is, overall, similar to the populations described in other observational studies. MCC management requires the involvement of several specialties. Increased awareness of MCC and standardization of its management are urgently needed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Author

Costanzo, Antonio, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Scuderi, Roberta, Zichichi, Leonardo, Papini, Manuela, Di Costanzo, Luisa, Conti, Andrea, Burlando, Martina, Chiricozzi, Andrea, Gaiani, Francesca Maria, Mugheddu, Cristina, Musumeci, Maria Letizia, Gisondi, Paolo, Piaserico, Stefano, Dapavo, Paolo, Venturini, Marina, Pagnanelli, Gianluca, Amerio, Paolo, Potenza, Concetta, Peris, Ketty, Cantoresi, Franca, Trevisini, Sara, Loconsole, Francesco, Offidani, Annamaria, Mercuri, Santo Raffaele, Lora, Viviana, Prignano, Francesca, Bartezaghi, Marta, Oliva, Giovanni, Aloisi, Elisabetta, Orsenigo, Roberto, Supreme study group, Matteo, Megna, Antonio, Costanzo, Filomena, Russo, Marco, Galluzzo, Luca, Stingeni, Roberta, Scuderi, Leonardo, Zichichi, Manuela, Papini, Luisa, Di Costanzo, Andrea, Conti, Martina, Burlando, Andrea, Chiricozzi, Francesca Maria, Gaiani, Cristina, Mugheddu, Maria Letizia, Musumeci, Paolo, Gisondi, Stefano, Piaserico, Paolo, Dapavo, Marina, Venturini, Gianluca, Pagnanelli, Paolo, Amerio, Concetta, Potenza, Ketty, Peri, Franca, Cantoresi, Sara, Trevisini, Francesco, Loconsole, Annamaria, Offidani, Santo Raffaele, Mercuri, Viviana, Lora, Francesca, Prignano, Marta, Bartezaghi, Giovanni, Oliva, Elisabetta, Aloisi, Roberto, Orsenigo, study group, Supreme, and Megna, Matteo

Subjects
medicine.medical_specialty, Psoriasis, secukinumab, PASI 90, Dermatology, Antibodies, Monoclonal, Humanized, Severity of Illness Index, interleukin-17A, Settore MED/35, Psoriasis Area and Severity Index, Psoriasis, Humans, Medicine, In patient, Plaque psoriasis, business.industry, secukinumab, Moderate to severe psoriasis, psoriasis, General Medicine, medicine.disease, humanities, Treatment Outcome, RL1-803, Secukinumab, Interleukin 17, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

Published
2021
Full Text
View/download PDF

8. Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy.

Author

Argenziano, Giuseppe, Amerio, Paolo, Aragone, Maria Grazia, Baggini, Ginevra, Baldari, Manuela, Castelli, Gianpiero, Coppola, Simmaco, Costanzo, Antonio, De Pasquale, Rocco, Fargnoli, Maria Concetta, Foti, Caterina, Giofrè, Claudia, Lembo, Serena, Leporati, Claudia, Loconsole, Francesco, Malara, Giovanna, Peris, Ketty, Richetta, Antonio Giovanni, Savoia, Paola, and Tiberio, Rossana

Subjects
*MEDICAL personnel, *MEDICAL personnel as patients, *PATIENT compliance, *PATIENT satisfaction, *DERMATOLOGISTS, *PSORIASIS
Abstract

Purpose: For patients with psoriasis, treatment adherence and persistence are fundamental if therapeutic goals are to be met. Patient Support Programs (PSPs) may be used as a support tool to assist patients and health care professionals optimize treatment and improve disease management. Patients and Methods: In Italy, the PSP PSOLife CARE, which began on the 9th of February 2017 and is ongoing, aimed to support patients with psoriasis under therapy with secukinumab (Cosentyx®). A team of medical professionals including Dermatologists, Psychologists, Nutritionists, and field Nurses provided outpatient treatment as well as remote support via phone calls. Patients had a standard duration in the Program of 6 months. This report analyzes the data of patients who benefited from the Program from February 2017 to August 2020, for a total observation of 42 months. Results: We provide here a descriptive report on the benefits of participation in the PSOLife CARE Program for patients with psoriasis and medical professionals involved in their care. Throughout their time in the PSOLife CARE Program, patient satisfaction remained consistently high with sustained improvements observed in all aspects of quality of life (ie emotional, social, physical, and economic). Despite exiting from the Program, most patients continued to adhere to secukinumab. Medical professionals also reported positive outcomes on their interactions with patients, with more than half of those surveyed rating the overall quality of the Program as "Outstanding". Conclusion: By supporting treatment adherence, the PSOLife CARE Program may have empowered patients to better manage their psoriasis, increasing their satisfaction with treatment and quality of life. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

9. Tattoo: Ancient art and current problems.

Author

Gualdi, Giulio, Fabiano, Antonella, Moro, Ruggero, Venturuzzo, Anna, Monari, Paola, Calzavara‐Pinton, Piergiacomo, and Amerio, Paolo

Subjects
ANCIENT art, TATTOOING, ALLERGIES
Abstract

The popularity of tattoos in the today's society brings with it a significant increase of the incidence of associated cutaneous reactions. Among the several complications that may occur after a tattooing procedure, allergic and photo‐allergic reactions, infections, and Koebner phenomenon are the most common ones observed. Most of these complications may be avoided by identifying, before tattooing, the presence of risk factors or comorbidities that may increase the risk of their onset. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

10. Treatment of Cutaneous Calciphylaxis with Sodium Thiosulfate.

Author

Auriemma, Matteo, Carbone, Angelo, Liberato, Lorenzo Di, Cupaiolo, Antonietta, Caponio, Chiara, Simone, Clara De, Tulli, Antonio, Bonomini, Mario, and Amerio, Paolo

Subjects
CALCIPHYLAXIS, CHRONIC kidney failure, DERMATOLOGY, DRUG administration, STAPHYLOCOCCAL diseases, DIAGNOSIS
Abstract

Cutaneous calciphylaxis is a potentially fatal condition characterized by calcium deposition in dermal arterioles and the subsequent development of livedo reticularis, plaques, and extremely painful ulcers. This condition may be present in up to 4% of end-stage renal disease patients. Several treatments, which mainly attempt to control calcium phosphate metabolism, are available for this condition. We describe two patients treated with sodium thiosulfate with good results. Moreover, we also performed a PubMed literature search of sodium thiosulfate treatment for calciphylaxis. We found 41 cases of which most (>90%) presented a rapid and sustained resolution, indicating this drug is a very good candidate for the treatment of this condition. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

11. Recognition of Depressive and Anxiety Disorders in Dermatological Outpatients.

Author

Picardi, Angelo, Amerio, Paolo, Baliva, Giannandrea, Barbieri, Claudio, Teofoli, Patrizia, Bolli, Simone, Salvatori, Valentina, Mazzotti, Eva, Pasquini, Paolo, and Abeni, Damiano

Subjects
*DERMATOLOGISTS, *DERMATOLOGY, *MENTAL illness, *DIAGNOSIS, *MENTAL health, *PATHOLOGICAL psychology
Abstract

Although mental disorders are frequent among dermatological patients, little is known about their recognition by dermatologists. This study aimed to assess dermatologists' ability to recognize depressive and anxiety disorders. All adult outpatients who visited four dermatologists on predetermined days ( n =317) completed the 12-item General Health Questionnaire (GHQ-12) and the section on depressive and anxiety disorders of the Patient Health Questionnaire (PHQ). Dermatologists, masked to GHQ-12 and PHQ scores, rated patients' mental health status. The analysis was performed on 277 patients (87%) with complete data. With the PHQ as criterion standard, the dermatologists' assessment sensitivity was 33%, while specificity was 76%. In most cases of disagreement between the dermatologists and the PHQ, the GHQ-12 corroborated the PHQ classification. Anxiety disorders tended to be recognized better than depressive disorders. Among patients with a PHQ diagnosis, male gender tended to be associated with misclassification by dermatologists. Although limitations inherent in self-report psychiatric assessment should be considered, this study suggests that mental disorders often go unrecognized in dermatological patients. This issue might be addressed by implementing specific training programmes, using validated screening questionnaires for depression and anxiety, and developing rational consultation-liaison services. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

12. Nail Psoriasis: Combined Therapy with Systemic Cyclosporin and Topical Calcipotriol.

Author

Feliciani, Claudio, Zampetti, Anna, Forleo, Pietro, Cerritelli, Luca, Amerio, Paolo, Proietto, Gianluca, Tulli, Antonio, and Amerio, Pierluigi

Subjects
PSORIASIS, SKIN diseases, NAIL diseases, IMMUNOSUPPRESSIVE agents, DERMATOLOGY, PATIENTS
Abstract

Background: Nail psoriasis is a common problem in psoriatic patients and often it is difficult to cure. Several treatments have been proposed in the last decade using new molecules like vitamin-D analog and/or immunosuppressive drugs both systemically and locally. Objective: Our goal was to evaluate a combination of cyclosporin and topical calcipotriol cream versus cyclosporin alone in a matched group of patients treated with cyclosporin alone. Méthod: Fifty-four patients affected by severe psoriasis and nail involvement were selected and matched for severity of nail involvement, sex, age, and cyclosporin dosage. Group A included 21 patients treated with cyclosporin alone (3.5 mg/kg/day) for three months. Group B included 33 patients treated with the same cyclosporin dosage plus, for the same time, topical application of calcipotriol cream twice a day. Evaluation for clinical improvement was the personal feeling of the patient after three months, while clinical appearance of the lesions was evaluated by the same dermatologist using digital pictures and who was blind as to the treatment of the patient. A score ranging from + to +++ was used in order to evaluate the improvement, and data were statistically evaluated with the Wilcoxon test. Results: Both cyclosporin alone and a combination of cyclosporin with topical calcipotriol twice a day were useful for treating nail psoriasis after three months of therapy although the combined therapy showed a better overall result in both mild and severe nail psoriasis. Improvement of the clinical appearance of the nail lesions was seen in about 79% of patients in group B (p ≤ 0.0004) versus about 47% of patients in group A (p ≤ 0.15). Conclusions: In patients with severe involvement of nail psoriasis we suggest the use of a combination of topical calcipotriol twice a day with systemic treatment such as cyclosporine. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

13. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study

Author

Luca Stingeni, Giovanna Malara, Andrea Conti, Luisa Di Costanzo, Carlo Giovanni Carrera, Martina Burlando, Piergiorgio Malagoli, Maria Letizia Musumeci, Federico Bardazzi, Valeria Brazzelli, Paolo Amerio, Clara De Simone, Sara Trevisini, Anna Balato, Matteo Megna, Francesco Loconsole, Catia De Felice, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo, Stingeni, Luca, Malara, Giovanna, Conti, Andrea, Di Costanzo, Luisa, Carrera, Carlo Giovanni, Burlando, Martina, Malagoli, Piergiorgio, Musumeci, Maria Letizia, Bardazzi, Federico, Brazzelli, Valeria, Amerio, Paolo, De Simone, Clara, Trevisini, Sara, Balato, Anna, Megna, Matteo, Loconsole, Francesco, De Felice, Catia, Bartezaghi, Marta, Rausa, Alice, Aloisi, Elisabetta, Orsenigo, Roberto, and Costanzo, Antonio

Subjects
Hospital Anxiety and Depression Scale, Clinical, Cosmetic and Investigational Dermatology, patient-reported outcomes, Dermatology Quality of Life Index, PASI, Dermatology, patient-reported outcome, plaque psoriasis
Abstract

Luca Stingeni,1 Giovanna Malara,2,3 Andrea Conti,4 Luisa Di Costanzo,5 Carlo Giovanni Carrera,6 Martina Burlando,7 Piergiorgio Malagoli,8 Maria Letizia Musumeci,9 Federico Bardazzi,10 Valeria Brazzelli,11 Paolo Amerio,12 Clara De Simone,13,14 Sara Trevisini,15 Anna Balato,16 Matteo Megna,17 Francesco Loconsole,18 Catia De Felice,19 Marta Bartezaghi,20 Alice Rausa,20 Elisabetta Aloisi,20 Roberto Orsenigo,20 Antonio Costanzo21,22 On behalf of the SUPREME Study Group1Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy; 2Dermatology Unit, Hospital “Bianchi Melacrino Morelli”, Reggio Calabria, Italy; 3Department of Dermatology, Papardo Hospital, Messina, Italy; 4Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini, Italy; 5Department of Dermatology, “Gaetano Rummo” Hospital, Benevento UOC Dermatologia, AO G. Rummo, Benevento, Italy; 6U.O. Dermatologia, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 7IRCCS San Martino Polyclinic Hospital, Di.S.Sal. Section of Dermatology, Genoa, Italy; 8Dermatology Unit IRCCS Policlinico San Donato, Milan, Italy; 9Dermatology Clinic, University of Catania, Catania, Italy; 10Division of Dermatology, University Hospital Policlinico “S. Orsola-Malpighi”, Bologna, Italy; 11Institute of Dermatology, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 12Dermatologic Clinic, G. D’Annunzio University, Chieti, Italy; 13Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 14Fondazione Policlinico Universitario A. Gemelli – IRCCS, Rome, Italy; 15Dermatology Department, University of Trieste, Trieste, Italy; 16Dermatology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy; 17Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 18Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; 19Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy; 20Novartis Farma SpA, Origgio, Italy; 21Unit of Dermatology, IRCCS Humanitas Research Hospital, Milan, Italy; 22Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence: Luca Stingeni, Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy, Tel +39075-5783881, Email luca.stingeni@unipg.itPurpose: Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24.Patients and Methods: The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test.Results: Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; P< 0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; P=0.0779) and 24 (83.2% vs 79.7%; P=0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (− 10.9 vs − 8.1, respectively, in females vs males; P=0.0004).Conclusion: In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.Keywords: plaque psoriasis, PASI, patient-reported outcomes, Dermatology Quality of Life Index, Hospital Anxiety and Depression Scale

Published
2023

14. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Author

Luca Stingeni, Andrea Chiricozzi, Piergiorgio Malagoli, Anna Campanati, Marina Venturini, Antonio Costanzo, Anna Balato, Paolo Gisondi, Clara De Simone, Giampiero Girolomoni, Maria Letizia Musumeci, Aurora Parodi, Franco Rongioletti, Angelo Cattaneo, Claudia Lasagni, Santo Raffaele Mercuri, Valentina Dini, Francesca Prignano, Federico Bardazzi, Concetta Potenza, Claudio Guarneri, Ada Lo Schiavo, Ketty Peris, A. M. Offidani, Manuela Papini, Paolo Dapavo, Francesco Loconsole, Maria Laura Flori, Francesco Cusano, Maria Concetta Fargnoli, Stefano Piaserico, Marco Galluzzo, Paolo Amerio, Piergiacomo Calzavara Pinton, Luca Bianchi, Marina Talamonti, Luigi Naldi, Rossana Tiberio, G. Malara, Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria C, Flori, Maria L, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Lo Schiavo, Ada, Malagoli, Piergiorgio, Malara, Giovanna, Mercuri, Santo R, Musumeci, Maria L, Naldi, Luigi, Papini, Manuela, Parodi, Aurora, Potenza, Concetta, Prignano, Francesca, Rongioletti, Franco, Stingeni, Luca, Tiberio, Rossana, Venturini, Marina, Bianchi, Luca, Costanzo, Antonio, Cusano, Francesco, Girolomoni, Giampiero, Offidani, Anna M, Peris, Ketty, Gisondi, P., Talamonti, M., Chiricozzi, A., Piaserico, S., Amerio, P., Balato, A., Bardazzi, F., Calzavara Pinton, P., Campanati, A., Cattaneo, A., Dapavo, P., De Simone, C., Dini, V., Fargnoli, M. C., Flori, M. L., Galluzzo, M., Guarneri, C., Lasagni, C., Loconsole, F., Lo Schiavo, A., Malagoli, P., Malara, G., Mercuri, S. R., Musumeci, M. L., Naldi, L., Papini, M., Parodi, A., Potenza, C., Prignano, F., Rongioletti, F., Stingeni, L., Tiberio, R., Venturini, M., Bianchi, L., Costanzo, A., Cusano, F., Girolomoni, G., Offidani, A. M., and Peris, K.

Subjects
Quality of life, Moderate to severe, medicine.medical_specialty, Consensus, Delphi method, Consensu, Dermatology, Plaque psoriasis, Systemic inflammation, Treat-to-target, 030207 dermatology & venereal diseases, 03 medical and health sciences, Settore MED/35, 0302 clinical medicine, Quality of life (healthcare), Psoriasis Area and Severity Index, Psoriasis, consensus, plaque psoriasis, quality of life, systemic inflammation, treatto-target, medicine, Intensive care medicine, Original Research, business.industry, Treat to target, Dermatology Life Quality Index, medicine.disease, Plaque psoriasi, 030220 oncology & carcinogenesis, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract

Introduction: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations. Methods: On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement). Results: Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy. Conclusion: These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.

Published
2021
Full Text
View/download PDF

15. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

Author

M Talamonti, G Malara, Y Natalini, F Bardazzi, A Conti, A Chiricozzi, C Mugheddu, P Gisondi, S Piaserico, G Pagnanelli, P Amerio, C Potenza, F Cantoresi, M Fargnoli, A Balato, F Loconsole, A Offidani, C Bonifati, F Prignano, M Bartezaghi, A Rausa, E Aloisi, R Orsenigo, A Costanzo, f Group, Talamonti, Marina, Malara, Giovanna, Natalini, Ylenia, Bardazzi, Federico, Conti, Andrea, Chiricozzi, Andrea, Mugheddu, Cristina, Gisondi, Paolo, Piaserico, Stefano, Pagnanelli, Gianluca, Amerio, Paolo, Potenza, Concetta, Cantoresi, Franca, Fargnoli, Maria Concetta, Balato, Anna, Loconsole, Francesco, Offidani, Annamaria, Bonifati, Claudio, Prignano, Francesca, Bartezaghi, Marta, Rausa, Alice, Aloisi, Elisabetta, Orsenigo, Roberto, and Costanzo, Antonio

Subjects
depression, psoriasis, quality of life, secukinumab, anxiety, medicine.medical_specialty, Anxiety, Depression, Psoriasis, Quality of life, Secukinumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Italy, Perception, Prospective Studies, Quality of Life, Severity of Illness Index, Treatment Outcome, Dermatology, Hospital Anxiety and Depression Scale, Antibodies, Settore MED/35, Internal medicine, Post-hoc analysis, Monoclonal, Medicine, Prospective cohort study, Humanized, Depression (differential diagnoses), psoriasi, business.industry, General Medicine, medicine.disease, RL1-803, medicine.symptom, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period of up to 72 weeks. Assessments used were: Psoriasis Area Sever-ity Index (PASI), Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A), and HADS - Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADS-A or HADS-D ≥ 11) were free of moderate to severe symptoms at weeks 16 and 48. The PASI and DLQI scores reduced over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS.

Published
2020

16. Eccrine syringofibroadenoma radiation treatment of an unusual presentation

Author

Guido Massi, Francesco Deodato, Gabriella Macchia, Fulvio R. Martone, Vincenzo Picardi, Alessio G. Morganti, Maria De Ninno, Arnaldo Carbone, A. Tulli, Giuseppina Sallustio, Paolo Amerio, Morganti, Alessio G., Martone, Fulvio R., Macchia, Gabriella, Carbone, Arnaldo, Massi, Guido, De Ninno, Maria, Deodato, Francesco, Picardi, Vincenzo, Sallustio, Giuseppina, Tulli, Antonio, and Amerio, Paolo

Subjects
ESFA, medicine.medical_specialty, Syringofibroadenoma, medicine.medical_treatment, Sweat Gland Neoplasm, Dermatology, Eccrine Glands, Foot Diseases, Syringoma, medicine, Humans, Obesity, Aged, Eccrine syringofibroadenoma, Radiotherapy, business.industry, General Medicine, medicine.disease, Fibroadenoma, Bilateral eccrine syringofibroadenoma, Nonsurgical treatment, Surgery, Radiation therapy, Sweat Gland Neoplasms, Foot Disease, Female, Eccrine Gland, Presentation (obstetrics), business, Human
Abstract

Benign skin diseases have seldom been treated with radiotherapy, unless resistant to other treatments. Eccrine syringofibroadenoma (ESFA) is a rare benign eccrine tumor. ESFA very rarely presents bilateral lesions, and seldom a nonsurgical treatment has been proposed. An exceptional case of bilateral ESFA of the foot is presented; radiotherapy was effective in treating both lesions with good cosmetic results. © 2010 Wiley Periodicals, Inc.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results